– JAPAN, Tokyo – LUCA Science, a company developing functional mitochondria as therapeutic agents, an emerging platform to treat damaged tissues and organs, today announced the closing of a $9.8 million Series A financing round led by Axil Capital Partners alongside other participating investors including Remiges Ventures, Nippon Venture Capital, Fast Track Initiative and CaHC.
LUCA Science is a preclinical stage1 biopharmaceutical company focusing on the discovery of novel mitochondria therapy to treat diseases and injuries in multiple therapeutic areas.
Mitochondria are the power plants in our cells that produce energy for our bodies. These small intracellular organelles house cellular aerobic respiration, the process used to turn oxygen and nutrients into energy. Recent research has shown that supplying highly functional mitochondria to injured tissues helps to stimulate cell activation and restore normal function.
Myocardial and cerebral infarction are the leading causes of death in the world. In recent years, lifestyle-related diseases and aging have been drawing attention to the onset and progression of these diseases. Ischemia, which is the cause of these diseases, is a condition in which blood flow is temporarily stopped and oxygen supply to the tissues is interrupted, resulting in hypoxia. The brain and heart tissues have high energy demand and react very sensitively to oxygen deficiency. This makes them most susceptible to reperfusion injury, when oxidative stress triggers cell necrosis due to mitochondrial damage, resulting in irreversible functional and tissue injury. Furthermore, dysfunction in mitochondria from a genetic mutation, environmental stress, or aging is associated with a variety of diseases.
LUCA Science is developing an innovative platform of highly functional mitochondrial using proprietary technologies. LUCA Science’s mitochondria can be stored and delivered as a biopharmaceutical agent. In addition, LUCA’s unique mitochondrial engineering technology can enhance the quality and function of mitochondria, all the way from its cell source to the target site of delivery. With the functional mitochondria as a therapeutic agent to restore cellular bioenergetics in dysfunctional or damaged tissues and organs, it will be possible to treat myocardial and cerebral infarction, immune cell exhaustion from cancer and infectious diseases, and other unmet medical needs.
LUCA Science is actively collaborating with both Japanese and international academic institutions to develop clinical applications in multiple therapeutic areas. With this round of funding, the research and development of advanced drug delivery and formulation will be accelerated to realize the goal of enabling functional mitochondria as therapeutic agents.
The preclinical stage is a stage in the drug development. After drug discovery research, the stability, safety, and efficacy of a drug are confirmed, and then the development and research stage is conducted before clinical research and the exploration of production technologies.
For more information: https://www.luca-science.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.